These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 23561470)
1. Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. Riches JC; Gribben JG Hematol Oncol Clin North Am; 2013 Apr; 27(2):207-35. PubMed ID: 23561470 [TBL] [Abstract][Full Text] [Related]
2. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Bartik MM; Welker D; Kay NE Semin Oncol; 1998 Feb; 25(1):27-33. PubMed ID: 9482524 [TBL] [Abstract][Full Text] [Related]
3. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. Sportoletti P; De Falco F; Del Papa B; Baldoni S; Guarente V; Marra A; Dorillo E; Rompietti C; Adamo FM; Ruggeri L; Di Ianni M; Rosati E Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206399 [TBL] [Abstract][Full Text] [Related]
4. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword. Vlachonikola E; Stamatopoulos K; Chatzidimitriou A Front Immunol; 2020; 11():612244. PubMed ID: 33552073 [TBL] [Abstract][Full Text] [Related]
5. An update on current and prospective immunotherapies for chronic lymphocytic leukemia. Emole JN; Locke FL; Pinilla-Ibarz J Immunotherapy; 2015; 7(4):455-66. PubMed ID: 25917633 [TBL] [Abstract][Full Text] [Related]
6. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Shah N; Rezvani K; Hosing C; Kebriaei P; Wierda W; Cooper L; Shpall E Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl(Suppl):S18-22. PubMed ID: 25486950 [TBL] [Abstract][Full Text] [Related]
7. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia. Singh N; Frey NV; Grupp SA; Maude SL Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534 [TBL] [Abstract][Full Text] [Related]
8. Vaccine- and immune-based therapy in chronic lymphocytic leukemia. Le Dieu R; Gribben J Semin Oncol; 2006 Apr; 33(2):220-9. PubMed ID: 16616069 [TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia: Are We Any Closer to a Cure? Rhodes JM; Schuster SJ Cancer J; 2019; 25(6):436-441. PubMed ID: 31764125 [TBL] [Abstract][Full Text] [Related]
10. T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients. Damle RN; Temburni S; Banapour T; Paul S; Mongini PK; Allen SL; Kolitz JE; Rai KR; Chiorazzi N Blood; 2012 Sep; 120(12):2438-49. PubMed ID: 22875913 [TBL] [Abstract][Full Text] [Related]
11. Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function. Burton JD; Weitz CH; Kay NE Am J Hematol; 1989 Feb; 30(2):61-7. PubMed ID: 2783634 [TBL] [Abstract][Full Text] [Related]
12. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672 [TBL] [Abstract][Full Text] [Related]
13. Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy. Weinkove R; Brooks CR; Carter JM; Hermans IF; Ronchese F Haematologica; 2013 Mar; 98(3):376-84. PubMed ID: 23065503 [TBL] [Abstract][Full Text] [Related]
14. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Fais F; Morabito F; Stelitano C; Callea V; Zanardi S; Scudeletti M; Varese P; Ciccone E; Grossi CE Int J Cancer; 2004 Apr; 109(3):402-11. PubMed ID: 14961579 [TBL] [Abstract][Full Text] [Related]
15. Biology and treatment of chronic lymphocytic leukemia. Keating MJ; Chiorazzi N; Messmer B; Damle RN; Allen SL; Rai KR; Ferrarini M; Kipps TJ Hematology Am Soc Hematol Educ Program; 2003; ():153-75. PubMed ID: 14633781 [TBL] [Abstract][Full Text] [Related]
16. The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression. Rohrbacher L; Brauchle B; Ogrinc Wagner A; von Bergwelt-Baildon M; Bücklein VL; Subklewe M Front Immunol; 2021; 12():608625. PubMed ID: 33790890 [TBL] [Abstract][Full Text] [Related]
17. Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities. Reyes E; Prieto A; Carrion F; Garcia-Suarez J; Esquivel F; Alvarez-Mon M Am J Hematol; 1997 Aug; 55(4):175-82. PubMed ID: 9257876 [TBL] [Abstract][Full Text] [Related]
18. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047 [TBL] [Abstract][Full Text] [Related]
19. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. Ramsay AG; Johnson AJ; Lee AM; Gorgün G; Le Dieu R; Blum W; Byrd JC; Gribben JG J Clin Invest; 2008 Jul; 118(7):2427-37. PubMed ID: 18551193 [TBL] [Abstract][Full Text] [Related]
20. Novel insights into the biology of CLL. Lanasa MC Hematology Am Soc Hematol Educ Program; 2010; 2010():70-6. PubMed ID: 21239773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]